I can make it to the 18th hole without huffing and puffing! "I was not expecting insurance help
The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course
Hypoglycaemia : Retatrutide is not expected to cause hypoglycaemia on its own
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensityscore matched samples
However, if the patient experiences any serious side effects, the dose of the drug should be reduced or discontinued
Here are some groups who may find it particularly beneficial: Individuals Seeking Weight Management : The appetite regulation and blood sugar support provided by GLP-1 can aid in weight control